US-based Click Therapeutics has raised $52m in a Series B financing round led by H.I.G. BioHealth Partners and Accelmed Partners II.

The funding round saw participation from Health Catalyst Capital, Revelation Partners, and a biotechnology hedge fund.

The company’s existing investors, including Sanofi Ventures, K2 HealthVentures, Hikma Ventures, and Ridgetop Health, have participated in the Series B financing round.

Click Therapeutics is engaged in the development of digital prescription medical treatments for patients with chronic pain, autoimmune disorders and other health conditions.

The company will use the funding to fast-track the development and commercialisation of its internal prescription digital therapeutic pipeline and advance platform capabilities.

Click Therapeutics co-founder and CEO David Benshoof Klein said: “Closing our Series B is an important milestone for Click that will allow us to further scale our proprietary Click Neurobehavioral Intervention (CNI) Platform and fund the development of new and innovative digital therapeutics for patients in need.

“We are excited to welcome our new investors and deepen our relationships with existing investors, all of whom share our vision of a new healthcare landscape in which prescription digital therapeutics play a prominent role alongside traditional pharmacological treatments.”

Click said that its pipeline of digital therapeutics spans several therapeutic areas, ranging from psychiatry and chronic pain to cardiometabolic and autoimmune disorders.

The company signed collaboration deals with Japan-based Otsuka Pharmaceutical to develop and commercialise a prescription digital therapeutic for the treatment of major depressive disorder (MDD).

Click also inked deals with Boehringer Ingelheim to develop and commercialise a prescription-based digital therapeutic to support the treatment of schizophrenia.

In addition to the Series B financing, H.I.G. BioHealth managing director Alex Zisson and Accelmed founder and managing partner Dr. Uri Geiger will join Click’s board of directors.

Zisson said: “Digital therapeutics hold the promise to change the very paradigm of healthcare. Click has one of the very best platforms in this field, and we are excited to help the company improve patient outcomes and potentially lower healthcare costs.”

Dr Geiger said: “Click is a prime example of the tremendous and growing potential for digital health software applications to enhance the lives of patients suffering from a variety of medical conditions.

“Click is the ideal partner for Accelmed due to our shared belief that leveraging technology in healthcare improves patient outcomes and increases efficiencies throughout the healthcare system.

“We are excited to offer our financial and operational expertise and to work closely with David and the entire Click executive team to support the growth of Click’s innovative platform.”